Earnings ·
Alcon reports Q3 sales of $2.7 billion and acquires Neurotech for $550 million
ALCAlcon Inc
Alcon reported third-quarter 2026 net sales of $2.717 billion, a 5% increase on both a reported and constant currency basis compared to the prior year period. Diluted earnings per share were $0.54, up 13%, while core diluted EPS rose 15% to $0.91. For the first nine months of 2026, sales reached $8.184 billion, a 7% increase, with core diluted EPS growing 14% to $2.60. The company also announced the acquisition of Neurotech Pharmaceuticals for $550 million in cash plus potential milestones, expanding its retinal disease portfolio. Additionally, Alcon returned $748 million to shareholders year-to-date through dividends and share repurchases.